top of page

Proposed IRA Expansion Would Cripple Biopharma, Lead to Fewer Drugs: Report

The proposed expansion to the Inflation Reduction Act would substantially harm U.S. biopharma, triggering hundreds of thousands of job cuts across the industry and leading to fewer innovative treatments in critical therapeutic areas, according to a new report released Thursday by healthcare consultancy Vital Transformation.


We Work For Health brings together national and local business leaders, labor, biopharma, patient advocacy, and other healthcare-related stakeholders to support policies and initiatives that foster innovation and facilitate the delivery of lifesaving and life-enhancing medicines. 

We Work For Health. © 2023 All Rights Reserved.

Privacy

Terms of Use

bottom of page